Pemafibrate Intermediates

Home / About Us / Application / Pemafibrate Intermediates

Pemafibrate intermediates

n-butyl-(S)-2-hydroxybutyrate

(S)-2-Hydroxybutanoic acid butyl ester

CAS#132513-51-0

Pemafibrate Intermediates

3-(4-methoxyphenoxy)propylamine

CAS#100841-00-7

Pemafibrate Intermediates

Green-chemistry and friendly reaction

K-877, Pemafibrate was marketed as Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals. In 3 July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan.

Pemafibrate (K-877) was designed to have a favorable benefit-risk balance and is now approved for the treatment of hyperlipidemia in Japan in 3rd, July 2017. Compared to other PPARα agonists, Pemafibrate does not significantly increase, and may even decrease, alanine aminotransferase (ALT) or γ-glutamyltransferase (γ-GT) levels. Moreover, unlike many other PPARα agonists, Pemafibrate is principally excreted via the liver and exposure to Pemafibrate is not dependent on the severity of renal dysfunction.

n-butyl-(S)-2-hydroxybutyrate (Material Code: PMBT-01) and 3-(4 -methoxyphenoxy) propylamine (Material Code:PMBT-02) are main starting materials of Pemafibrate. The green chemistry was well developed and successfully applied which makes the manufacturing process more friendly and adorable to the environment.

None

Latest Application

Thioether Diols

Thioether diols including 2–4 thioether units are developed and used to prepare crown oxathioethers by reaction with the expected group.

Barluenga Reagent

Bis(2,4,6-trimethylpyridine)iodine(I) hexafluorophosphate

Pemafibrate Intermediates

K-877, Pemafibrate was marketed as Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist.

Hot Products